Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)

• Status: Completed
• Trial end date: 2017-10-16

Summary

This study seeks to develop a new induction chemotherapy regimen which is a combination of two pill drugs taken by mouth and two drugs given by vein. This is a phase I study, which means that the primary goal is to establish the recommended dose of an investigational drug when added to chemotherapy. The researchers wish to evaluate the effects, good and bad, of the investigational drug.

• Phase: Phase 1

Details

• Lead Sponsor: Memorial Sloan Kettering Cancer Center
• Collaborators: Boehringer Ingelheim; National Comprehensive Cancer Network
• Treatments: Afatinib; Albumin-Bound Paclitaxel; Carboplatin; Paclitaxel; Ribavirin